Name | No. | For Patients with | Purpose |
---|---|---|---|
“XPORT” – ENGOT-EN20/GOG-3083/XPORT-EC-042 | 22-08 | p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma. When we say someone has p53 wildtype cancer, it means their guardian (p53) is working as it should. It’s like having a strong and reliable guardian who can keep an eye on things and prevent trouble (like stopping cells from growing out of control). So, in simple terms, p53 wildtype cancer means the guardian in the body is doing its job properly, but still, cancer has somehow developed. |
The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wildtype endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomised in a 1:1 ratio to maintenance therapy with either Selinexor or placebo. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-09 ADEPPT | 22-09 | Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2] |
The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2). |
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-15 PLAN | 22-15 | Advanced or locally advanced Non-Small Cell Lung Cancer |
Purpose of this study is to evaluate whether plasma genotyping via an in-house next generation sequencing (NGS) panel, will identify actionable genomic alterations in patients with newly diagnosed advanced or locally advanced non-squamous NSCLC |
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-23 NeoCOAST-2 | 22-23 | Early-Stage (II to IIIA) Non-small Cell Lung Cancer |
The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
23-12 LATIFY | 23-12 | patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy. |
The purpose of the study is to measure Overall Survival (OS). OS is defined as time from randomisation until the date of death due to any cause. The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS |
Name | No. | For Patients with | Purpose |
---|---|---|---|
AcceleRET-Lung | 20-21 | This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body. |
AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC). |
Name | No. | For Patients with | Purpose |
---|---|---|---|
AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
Name | No. | For Patients with | Purpose |
---|---|---|---|
Astellas 8951-CL-5201 | CTRIAL-IE 18-44 | Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL). |
Name | No. | For Patients with | Purpose |
---|---|---|---|
BRAND | 23-11 | Non-Small Cell Lung Cancer |
The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC |
Name | No. | For Patients with | Purpose |
---|---|---|---|
BRUIN CLL-322 | 20-21-44 | Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
CompARE | 17-14 | intermediate and high-risk oropharyngeal |
To examine the outcomes of alternative treatments aiming to improve overall survival time in intermediate and high-risk oropharyngeal cancer and to compare Quality of Life (QoL), toxicity outcomes and swallowing function of these alternative treatments |
Name | No. | For Patients with | Purpose |
---|---|---|---|
DASL HiCaP | CTRIAL-IE 19-32 | People aged 18 years or older with either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy. |
Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
DESTINY DS8201-A-U306 | 21-07 | HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer |
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
DP-IMRT Pancreas | 17-12 | resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma. |
to determine the maximum tolerated dose (MTD) defined by the number of radiotherapy-related ≥ Grade 3 acute toxicities assessed up to 4 weeks post RT. Once the MTD is established, patients will continue to be recruited at that dose level up to a total of 49 patients. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
ENGOT EN-9 |